Chimerix Inc
NASDAQ:CMRX

Watchlist Manager
Chimerix Inc Logo
Chimerix Inc
NASDAQ:CMRX
Watchlist
Price: 2.97 USD -0.67%
Market Cap: 267.1m USD
Have any thoughts about
Chimerix Inc?
Write Note

Chimerix Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chimerix Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Chimerix Inc
NASDAQ:CMRX
Cash from Operating Activities
-$70.3m
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
-7%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$842.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Chimerix Inc
Glance View

Market Cap
267.1m USD
Industry
Biotechnology

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.

CMRX Intrinsic Value
2.98 USD
Fairly Valued
Intrinsic Value
Price

See Also

What is Chimerix Inc's Cash from Operating Activities?
Cash from Operating Activities
-70.3m USD

Based on the financial report for Sep 30, 2024, Chimerix Inc's Cash from Operating Activities amounts to -70.3m USD.

What is Chimerix Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-7%

Over the last year, the Cash from Operating Activities growth was 6%. The average annual Cash from Operating Activities growth rates for Chimerix Inc have been 2% over the past three years , 3% over the past five years , and -7% over the past ten years .

Back to Top